BIOMAT Database Logo BIOMAT Database Logo

Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. 2012

Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Department of Radiation Oncology, Tsukuba University, Ibaraki, Japan. ooyoshiko@pmrc.tsukuba.ac.jp

BACKGROUND This study was performed retrospectively to evaluate the outcome of patients with stage III non-small cell lung cancer (NSCLC) after proton beam therapy (PBT) alone. METHODS The subjects were 57 patients with histologically confirmed NSCLC (stage IIIA/IIIB: 24/33) who received PBT without concurrent chemotherapy. The cohort included 32 cases of squamous cell carcinoma, 18 adenocarcinoma, and 7 non-small cell carcinoma. Lymph node metastases were N0 7, N1 5, N2 30, and N3 15. Planned total doses ranged from 50 to 84.5 GyE (median, 74 GyE). RESULTS Planned treatment was completed in 51 patients (89%). At the time of analysis, 20 patients were alive, and the median follow-up periods were 16.2 months for all patients and 22.2 months for survivors. The median overall survival period was 21.3 months (95% confidence interval: 14.2-28.4 months), and the 1- and 2-year overall survival rates were 65.5% (52.9-78.0%) and 39.4% (25.3-53.5%), respectively. Disease progression occurred in 38 patients, and the 1- and 2-year progression-free survival rates were 36.2% (23.1-49.4%) and 24.9% (12.7-37.2%), respectively. Local recurrence was observed in 13 patients, and the 1- and 2-year local control rates were 79.1% (66.8-91.3%) and 64.1% (47.5-80.7%), respectively. Grade ≥ 3 lung toxicity was seen in six patients, esophageal toxicity occurred at grade ≤ 2, and there was no cardiac toxicity. CONCLUSIONS The prognosis of patients with unresectable stage III NSCLC is poor without chemotherapy. Our data suggest that high-dose PBT is beneficial and tolerable for these patients.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D012062 Relative Biological Effectiveness The ratio of radiation dosages required to produce identical change based on a formula comparing other types of radiation with that of gamma or roentgen rays. Biological Effectiveness, Relative,Effectiveness, Biologic Relative,Effectiveness, Biological Relative,Relative Biologic Effectiveness,Biologic Effectiveness, Relative,Biologic Relative Effectiveness,Biological Relative Effectiveness,Effectiveness, Relative Biologic,Effectiveness, Relative Biological,Relative Effectiveness, Biologic
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas

Related Publications

Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.
July 2016, Cancer science,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
August 2017, JAMA oncology,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Results of curative radiation therapy with or without chemotherapy for stage III unresectable non-small cell lung cancer.
October 2005, Cancer research and treatment,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Preliminary results of proton-beam therapy for stage III non-small-cell lung cancer.
October 2015, Current oncology (Toronto, Ont.),
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
July 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer.
December 2009, International journal of clinical oncology,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.
January 1999, Acta oncologica (Stockholm, Sweden),
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Proton beam therapy of Stage II and III non-small-cell lung cancer.
November 2011, International journal of radiation oncology, biology, physics,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
June 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Yoshiko Oshiro, and Masashi Mizumoto, and Toshiyuki Okumura, and Takayuki Hashimoto, and Nobuyoshi Fukumitsu, and Ayako Ohkawa, and Ayae Kanemoto, and Haruko Hashii, and Toshiki Ohno, and Takeji Sakae, and Koji Tsuboi, and Hideyuki Sakurai
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.
October 2011, Cancer,
Copied contents to your clipboard!